Craig Gracey, serving as the Chief Accounting Officer for Omada Health, Inc. (NASDAQ:OMDA), completed a transaction involving the sale of 2,083 shares of the company's common stock. This event took place on June 24, 2026. The total monetary value associated with the shares sold was recorded at $39,601. The execution of these shares occurred within a specific price band. The shares were sold at prices ranging from $19.00 to $19.03 per share. The weighted average price for the transaction was calculated at $19.0118 per share. This sale was carried out in accordance with a 10b5-1 trading plan. Mr. Gracey originally adopted this specific plan on March 13, 2026. Following the completion of this sale, Mr. Gracey retains direct ownership of 5,025 shares of Omada Health common stock.
Key Market and Sector Developments
The transaction by the Chief Accounting Officer occurs during a period of notable price movement for Omada Health. The stock has demonstrated recent momentum, with the current trading price reaching $20.89. This level represents an increase from the $19 range that was active during the time of Mr. Gracey's sale. Market data indicates that the company has delivered a 32% return for the year to date. Current valuation metrics suggest the stock is trading above its calculated Fair Value. These financial movements place the digital health sector under scrutiny for growth trajectories and valuation adjustments.
Financial Performance and Analyst Activity
Omada Health recently disclosed its financial results for the first quarter of 2026. The report highlighted a positive earnings surprise. The company achieved an earnings per share of -$0.05. This figure exceeded the anticipated earnings per share of -$0.08. Revenue performance also showed significant expansion. Omada Health's revenue reached $78 million. This amount represents a 42% increase compared to the previous year. In parallel with these financial disclosures, Citizens adjusted its outlook for the company. The firm raised its price target for Omada Health to $21 from $18. The rating maintained by the analyst remains a Market Outperform. The analyst noted that the company is currently trading at 2.5 times the firm's 2026 revenue estimate. This activity impacts the broader healthcare technology market where valuation multiples are closely monitored.
Corporate Governance and Strategic Outlook
Corporate governance updates also accompanied the financial developments. Omada Health conducted its 2026 Annual Meeting of Stockholders. During this meeting, Sean Duffy and Trevor Fetter were elected as Class I Directors. These newly elected directors are set to serve until the 2029 annual meeting. These events reflect a period of growth and strategic decisions for Omada Health. The combination of executive transactions, financial beats, and governance changes provides a comprehensive view of the company's current standing.